1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 17, 29/Apr/2021
  4. Article
Editorial Open Access
Like 0
Download
Preview this article:
Preview Magnify

There is no abstract available.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.17.2100430
2021-04-29
2024-11-08
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.17.2100430
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/17/eurosurv-26-17-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.17.2100430&mimeType=html&fmt=ahah

References

  1. Cohen J. Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak. AAAS; 2020. Available from: https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genome-virus-implicated-wuhan-pneumonia-outbreak
  2. World Health Organization (WHO). WHO candidate tracker COVID-19 – Landscape of novel coronavirus candidate vaccine development worldwide. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  3. European Medicines Agency (EMA). EMA Guidance for medicine developers and other stakeholders on COVID-19. Amsterdam: EMA; 2020. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/guidance-medicine-developers-other-stakeholders-covid-19
  4. European Medicines Agency (EMA). EMA COVID-19: latest updates. Amsterdam: EMA; 2020. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates
  5. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;S0140-6736(21)00677-2.  https://doi.org/10.1016/S0140-6736(21)00677-2 
  6. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA 1273 COVID-19 Vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers – eight US locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500.  https://doi.org/10.15585/mmwr.mm7013e3  PMID: 33793460 
  7. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. , ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;  https://doi.org/10.1056/NEJMoa2101544  PMID: 33882225 
  8. European Centre for Disease Prevention and Control (ECDC). ECDC COVID-19 Vaccine tracker. Stockholm: ECDC. [Accessed: 28 Apr 2021]. Available from: https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
  9. COVAX. A global risk-sharing mechanism from pooled procurement and equitable distribution of COVID-19 vaccines. Geneva: Gavi. [Accessed: 28 Apr 2021]. Available from: https://www.gavi.org/covax-facility
  10. World Health Organization (WHO). WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination
  11. World Health Organization (WHO). WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply. Geneva: WHO; 13 Nov 2020. Available from: https://www.who.int/publications/m/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply-
  12. European Centre for Disease Prevention and Control (ECDC). EU/EEA NITAG Collaboration. Stockholm: ECDC. [Accessed: 28 Apr 2021]. Available from: https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/national-immunisation-technical-advisory-groups-nitag
  13. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;NEJMoa2104882.  https://doi.org/10.1056/NEJMoa2104882  PMID: 33835768 
  14. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;  https://doi.org/10.1056/NEJMoa2104840  PMID: 33835769 
  15. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;NEJMoa2105385.  https://doi.org/10.1056/NEJMoa2105385  PMID: 33861525 
  16. European Medicines Agency (EMA). Vaxzevria. Summary of product characteristics. Amsterdam: EMA. [Accessed: 28 Apr 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf
  17. Our world in data. England: Global Change Data Lab. [Accessed: 28 Apr 2021]. Available from: https://ourworldindata.org/
  18. World Health Organization (WHO). WHO R&D Blueprint COVID-19 new variants: Knowledge gaps and research. Geneva: WHO; 12 Jan 2021. Available from: https://cdn.who.int/media/docs/default-source/blue-print/covid-19-new-variants-meeting-report_20.03.2012.pdf?sfvrsn=5ac5785_3&download=true
  19. World Health Organization (WHO). Statement on the seventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. Geneva: WHO; 19 Apr 2021. Available from: https://www.who.int/news/item/19-04-2021-statement-on-the-seventh-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
  20. World Health Organization (WHO). WHO Weekly Epi Update from 13 April. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-april-2021
  21. United States Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants. Washington: 22 Feb 2021. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus
  22. European Medicines Agency (EMA). Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2. Amsterdam: EMA; 25 Feb 2021. Available from: https://www.ema.europa.eu/en/regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2
  23. European Medicines Agency (EMA). EMA and ECDC join forces for enhanced post-marketing monitoring of COVID-19 vaccines in Europe. Amsterdam: EMA; 26 Apr 2021. Available from: https://www.ema.europa.eu/en/news/ema-ecdc-join-forces-enhanced-post-marketing-monitoring-covid-19-vaccines-europe
  24. Moyo-Gwete T, Madzivhandila M, Makhado Z. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies; bioRxiv; 2021. Available from: https://www.biorxiv.org/content/10.1101/2021.03.06.434193v1
  25. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al.; Network for Genomic Surveillance in South Africa. COMMIT-KZN Team. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021.  https://doi.org/10.1038/s41586-021-03471-w  PMID: 33780970 
  26. European Centre for Disease Prevention and Control (ECDC). ECDC Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions. Stockholm: ECDC; 21 Apr 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Interim-guidance-benefits-of-full-vaccination-against-COVID-19-for-transmission-and-implications-for-non-pharmaceutical-interventions.pdf
  27. Rohleder S, Stock C, Bozorgmehr K. Socioeconomic deprivation is inversely associated with measles incidence: a longitudinal small-area analysis, Germany, 2001 to 2017. Euro Surveill. 2021;26(17):1900755.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.1900755 
  28. Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, Neuzil KM, Ortiz JR. National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. Euro Surveill. 2021;26(17):2001195.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2001195 
  29. von Linstow ML, Yde NA, Kirkby N, Eltvedt A, Nordmann WT, Bybeck NA, et al. Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019. Euro Surveill. 2021;26(17):2001167.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2001167 
  30. European Centre for Disease Prevention and Control (ECDC). Objectives of vaccination strategies against COVID-19. Stockholm: ECDC; 23 Apr 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/objectives-vaccination-strategies-against-covid-19
  31. Robert Koch Institut (RKI). Standard Operating Procedure of the German Standing Committee on Vaccinations (STIKO) for the systematic development of vaccination recommendations, Version 3.1. Berlin: RKI; 14 Nov 2018. Available from: https://www.rki.de/EN/Content/infections/Vaccination/methodology/SOP.pdf?__blob=publicationFile
No country or continent is on its own in the ongoing COVID-19 pandemic
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Kari+Johansen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Johansen Kari</a>, <a href="/search?value1=Hanna+Nohynek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nohynek Hanna</a></span>. No country or continent is on its own in the ongoing COVID-19 pandemic. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(17):pii=2100430. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100430" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100430</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 29 Apr 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 29 Apr 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.17.2100430
/content/10.2807/1560-7917.ES.2021.26.17.2100430
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error